Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome.

Hormone research - 1 Jan 2003

Grigorescu-Sido Anca, Bettendorf Markus, Schulze Egbert, Duncea Ileana, Heinrich Udo

Abstract excerpt

OBJECTIVE: To evaluate the impact of hydrocortisone dosage, age at diagnosis, compliance, genotype and phenotype on growth and height outcome in 21-hydroxylase-deficient patients. METHODS: We analyzed 37 patients with 21-hydroxylase deficiency (17 had completed growth, 20 still growing). Final (FH)/predicted final height (pFH) and loss of height potential related to target height (TH) were calculated and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Height
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Follow-Up Studies

Share to Hydrocortisone

Share to Infant

Share to Metabolism, Inborn Errors

Share to Steroid 21-Hydroxylase

Source

Identifiers

PMID: 12876419
DOI: 10.1159/000071876

Genes

SDS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome.PMID 12876419Read ↗

Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience.Semantic proximity Read ↗

Newborn screening-detected 21-hydroxylase deficiency: growth pattern is not associated with the genotype.Semantic proximity Read ↗

Growth and Treatment in Congenital Adrenal Hyperplasia: An Observational Study from Diagnosis to Final Height.Semantic proximity Read ↗

Adult height of subjects with nonclassical 21-hydroxylase deficiency.Semantic proximity Read ↗

CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency.Semantic proximity Read ↗

Clinical, biochemical and genetic features with nonclassical 21-hydroxylase deficiency and final height.Semantic proximity Read ↗

Prolongation of growth by treatment of 11-hydroxylase deficiency with depot-leuprolide, growth hormone, and hydrocortisone.Semantic proximity Read ↗

Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone.Semantic proximity Read ↗

Female pseudohermaphroditism and inefficient peak bone mass in an untreated subject affected by 21-hydroxylase congenital adrenal hyperplasia.Semantic proximity Read ↗

Fractures and bone mineral density in adult women with 21-hydroxylase deficiency.Semantic proximity Read ↗

Long term outcome in adult males with classic congenital adrenal hyperplasia.Semantic proximity Read ↗

GH therapy in Noonan syndrome: Review of final height data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.